Symbiotec Pharmalab Share Price Today

Knovea signs US commercialisation pact for two dual chamber vials

Knovea, a subsidiary of Symbiotec Pharmalab, signed a commercialisation agreement. The deal covers sales of two dual chamber vial products in the United States. Partner is a major global pharmaceutical company.

Symbiotec Pharmalab receives US FDA VAI status for Pithampur plant

Symbiotec Pharmalab received VAI status from US FDA for its Pithampur facility. Inspection was conducted from August 10 to August 14, 2026. VAI status indicates no mandatory regulatory action is required by the agency.

Symbiotec Pharmalab Q1FY27: Net profit down 53%, targets 20-25% growth

Consolidated net profit fell 53% YoY to ₹140.6 million in Q1FY27 due to new business costs. Revenue from operations grew 7.4% YoY to ₹2,181.5 million, driven by API segment. EBITDA margin contracted to 28.05% as opex and depreciation from new verticals weighed on profits. Management targets 20% revenue and 25% EBITDA growth for FY27, with new revenues starting H2FY27.

Symbiotec Pharmalab promoters re-create pledge over 10.45% stake post IPO

Promoters re-created pledge over 66.93 lakh shares (10.45%) post-IPO lock-in. Encumbrance held by Beacon Trusteeship for SHIPL debentures. Original pledge dated December 10, 2025, was temporarily released for IPO compliance. Includes pledges from three family trusts not listed in initial disclosure. Covenant requires promoters to hold 26% unencumbered equity to avoid debt repayment.

Symbiotec Pharmalab submits fair disclosure code effective December 2025

Symbiotec Pharmalab Limited submitted its fair disclosure code to BSE and NSE on September 3, 2026. The policy is effective from December 15, 2025, ensuring timely disclosure of price-sensitive information. Salil Jain, Company Secretary, signed the intimation letter under SEBI PIT Regulations 2015. The code mandates uniform dissemination of UPSI to prevent selective disclosure.

Mirae Asset Mutual Fund raises stake in Symbiotec Pharmalab to 6.22%

Mirae Asset Mutual Fund acquired 34,97,420 shares of Symbiotec Pharmalab Ltd. The acquisition was executed via the open market on September 1, 2026. Mirae Asset's total stake increased from 0.78% to 6.22% of total share capital. The fund's diluted stake rose from 0.77% to 6.21%. No warrants or convertible securities were part of this transaction.